NGM Biopharmaceuticals Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. NGM Biopharmaceuticals last-minute Real Value cannot be determined due to lack of data. The latest price of NGM Biopharmaceuticals is $0.0. Our model forecasts the value of NGM Biopharmaceuticals from inspecting the firm fundamentals such as return on equity of -0.7, and Operating Margin of (179.78) % as well as reviewing its technical indicators and probability of bankruptcy.
NGM Biopharmaceutica Total Value Analysis
NGM Biopharmaceuticals is now forecasted to have company total value of (36.13 M) with market capitalization of 128.53 M, debt of 5.38 M, and cash on hands of 297.81 M. The negative valuation of NGM Biopharmaceutica may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the NGM Biopharmaceutica fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(36.13 M) | 128.53 M | 5.38 M | 297.81 M |
NGM Biopharmaceutica Investor Information
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.86. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NGM Biopharmaceuticals recorded a loss per share of 1.73. The entity had not issued any dividends in recent years. Based on the key measurements obtained from NGM Biopharmaceutica's financial statements, NGM Biopharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.NGM Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NGM Biopharmaceutica has an asset utilization ratio of 2.62 percent. This suggests that the Company is making $0.0262 for each dollar of assets. An increasing asset utilization means that NGM Biopharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.NGM Biopharmaceutica Ownership Allocation
NGM Biopharmaceuticals maintains a total of 83.46 Million outstanding shares. Over half of NGM Biopharmaceutica's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NGM Biopharmaceutica Profitability Analysis
The company reported the last year's revenue of 4.42 M. Reported Net Loss for the year was (142.38 M) with loss before taxes, overhead, and interest of (125.73 M).NGM Biopharmaceutica Growth Indicators
Investing in growth stocks can be very risky. If the company such as NGM Biopharmaceutica does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 82.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |